Search results for "VIRUS DISEASE"

showing 10 items of 1907 documents

The experience of distress during the COVID-19 outbreak: a cross-country examination on the fear of COVID-19 and the sense of loneliness

2020

AbstractObjectivesTo examine gender, age and cross-country differences in fear of COVID-19 and sense of loneliness during the lockdown, by comparing people from countries with a high rate of infections and deaths (i.e. Spain and Italy) and from countries with a mild spread of infection (i.e. Croatia, Serbia, Slovakia, Slovenia, Bosnia and Herzegovina).MethodsA total of 3876 participants (63% female) completed an online survey on “Everyday life practices in COVID-19 time” in April 2020, including measures of fear of COVID-19 and loneliness.ResultsMales and females of all age groups in countries suffering from a strong impact of the COVID-19 pandemic reported higher fear of COVID-19 and sense…

DistressCoronavirus disease 2019 (COVID-19)Economic costPandemicmedicineOutbreakLonelinessmedicine.symptomPsychologyEveryday lifeMental healthDemography
researchProduct

Enumeration of NKG2C+natural killer cells early following allogeneic stem cell transplant recipients does not allow prediction of the occurrence of c…

2015

The role of Natural killer (NK) cells in the control of cytomegalovirus (CMV) infection in allogeneic stem cell transplant recipients has not been precisely characterized. The current study is aimed at investigating the potential role of NK cells expressing the activating receptor NKG2C in affording protection against the development of CMV DNAemia in patients exhibiting detectable CMV-specific CD8+ T-cell responses early following transplantation. A total of 61 nonconsecutive patients were included in the study. Peripheral levels of CD56brightCD16−/low and CD56dimCD16+ NKG2C+ NK cells and CMV pp65/IE-1-specific IFN-γ-producing CD8+ T-cells were enumerated by flow cytometry at days +30 and …

Dna loadAbsolute numbermedicine.diagnostic_testCongenital cytomegalovirus infectionvirus diseasesBiologymedicine.diseaseVirologyFlow cytometryTransplantationInfectious DiseasesVirologyImmunologymedicineIn patientStem cellCD8Journal of Medical Virology
researchProduct

Nanomedicine: A Diagnostic and Therapeutic Approach to COVID-19

2021

The SARS-CoV-2 virus is causing devastating morbidity and mortality worldwide. Nanomedicine approaches have a high potential to enhance conventional diagnostics, drugs and vaccines. In fact, lipid nanoparticle/mRNA vaccines are already widely used to protect from COVID-19. In this review, we present an overview of the taxonomy, structure, variants of concern, epidemiology, pathophysiology and detection methods of SARS-CoV-2. The efforts of repurposing, tailoring, and adapting pre-existing medications to battle COVID-19 and the state of vaccine developments are presented. Next, we discuss the broad concepts and limitations of how nanomedicine could address the COVID-19 threat. Nanomaterials …

DrugMedicine (General)Coronavirus disease 2019 (COVID-19)nanotechnologyComputer scienceSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)media_common.quotation_subjectDiagnostic testNanotechnologySARS-CoV-2 virusReviewGeneral Medicineacute respiratory distress syndromesepsisdrug delivery systemsR5-920vaccineMedicineNanomedicineInorganic materialsRepurposingmedia_commonAir filterFrontiers in Medicine
researchProduct

Hepatitis E Virus Detection in Liver Tissue from Patients with Suspected Drug-Induced Liver Injury

2015

Hepatitis E virus (HEV) infection is increasingly recognized as a cause of acute hepatitis in the industrialized world. We aimed to determine the frequency of acute Hepatitis E virus (HEV) infection in cases of suspected drug-induced liver injury (DILI), mainly a diagnosis of exclusion. To this aim, formalin-fixed, paraffin-embedded (FFPE) liver tissues of all cases routinely processed in our institute during a 2 ½ years period in which DILI was amongst the differential diagnoses (157 liver biopsies, one liver explant) were subjected to semi-nested RT-PCR for the detection of hepatitis E virus (HEV) RNA. Histopathology was re-evaluated on all cases tested positive. HEV RNA was detectable in…

DrugPathologymedicine.medical_specialtymedia_common.quotation_subjectviruses610 Medicine & health2700 General Medicinemedicine.disease_causeliverHepatitis E virushepatitis E virus infection10049 Institute of Pathology and Molecular PathologyGenotypeHepatitis E virusmedicinehepatitismedia_commonLiver injuryHepatitislcsh:R5-920molecular testingbusiness.industryvirus diseasesGeneral Medicinemedicine.diseaseDiagnosis of exclusiondigestive system diseasesOriginal Research in MedicineEtiologyMedicineHistopathologylcsh:Medicine (General)businessdrug-induced liver injuryFrontiers in Medicine
researchProduct

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Aciclovir

2008

Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing (biowaiver) for the approval of immediate release (IR) solid oral dosage forms containing aciclovir are reviewed. Aciclovir therapeutic use and therapeutic index, pharmacokinetic properties, data related to the possibility of excipient interactions and reported BE/bioavailability (BA) studies were also taken into consideration in order to ascertain whether a biowaiver can be recommended. According to the Biopharmaceutics Classification System (BCS) and considering tablet strengths up to 400 mg, aciclovir would be BCS Class III. However, in some countries also 800 mg tablets are available which …

Drugbusiness.industrymedia_common.quotation_subjectAcyclovirAdministration OralBiological Availabilityvirus diseasesPharmaceutical ScienceExcipientPharmacologyBioequivalenceBiopharmaceutics Classification SystemAntiviral AgentsDosage formTherapeutic EquivalencyPharmacokineticsmedicineRegulatory scienceAciclovirbusinessmedicine.drugmedia_commonJournal of Pharmaceutical Sciences
researchProduct

Autoimmune hepatitis triggered by COVID-19

2021

We present the case of a 60-year-old woman with no drug allergies or toxic habits, with hypothyroidism and receiving treatment with levothyroxine.

Drugendocrine system2019-20 coronavirus outbreakAllergyendocrine system diseasesCoronavirus disease 2019 (COVID-19)business.industrymedia_common.quotation_subjectSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)GastroenterologyMEDLINELevothyroxineGeneral MedicineAutoimmune hepatitismedicine.diseaseImmunologymedicinebusinesshormones hormone substitutes and hormone antagonistsmedia_commonmedicine.drugRevista Española de Enfermedades Digestivas
researchProduct

Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19

2020

Our coalition of public health experts, doctors, and scientists worldwide want to draw attention to the need for high-quality evaluation protocols of the potential beneficial effect of hydroxychloroquine (HCQ) as a post-exposure drug for exposed people. In the absence of an approved, recognized effective pre or post-exposure prophylactic drug or vaccine for COVID-19, nor of any approved and validated therapeutic drug, coupled with social and political pressure raised by publicity both regarding the potential beneficial effect of hydroxychloroquine (HCQ) as well as potential risks from HCQ, we urge the immediate proper clinical trials. Specifically, we mean using HCQ for post-exposure of peo…

Drugmedicine.medical_specialtyPost exposureCoronavirus disease 2019 (COVID-19)COVID19media_common.quotation_subject030231 tropical medicineHydroxychloroquine ; COVID-19 ; Chloroquine ; SARS-CoV2 ; antiviral ; malaria ; Systemic lupus erythematosus ; Immunomodulation ; CoronavirusLoading doseImmunomodulation03 medical and health sciencesSystemic lupus erythematosus0302 clinical medicineChloroquineInternal medicineMedicine030212 general & internal medicineCoronavirus malaria antiviralmedia_commonlcsh:R5-920business.industryStandard treatmentPublic Health Environmental and Occupational HealthChloroquineHydroxychloroquineClinical trialEditorialInfectious DiseasesSARS-CoV2lcsh:Medicine (General)businessHydroxychloroquinemedicine.drugOne Health
researchProduct

Weight-based dosing: Which impact on efficacy and safety of therapy?

2004

Abstract Pegylated interferons (PEG-IFNs) in combination with ribavirin represent the most recent advance in the treatment of patients withchronic hepatitis C (CHC): two large clinical trials have shown a superior efficacy in clearing HCV in almost 60% of treated naive patients. Responses to antiviral treatment of CHC vary according to both viral and host factors. Managing patients with CHC infection requires individualised treatment strategies to optimise outcomes. Several landmark publications on PEG-IFNs have reported that weight is a significant predictive factor for SVR in the treatment of CHC with fixed-dose drug administration. With fixed-dose treatment, there is a direct correlation…

Drugmedicine.medical_specialtymedia_common.quotation_subjectChronic hepatitis Cchemistry.chemical_compoundPegylated interferonInternal medicinemedicineDosingAdverse effectmedia_commonHepatologybusiness.industryWeight-based dosingRibavirinGastroenterologyvirus diseasesHepatitis Cmedicine.diseaseSurgeryClinical trialchemistrybusinessWeight based dosingPegylated interferonmedicine.drugDigestive and Liver Disease
researchProduct

7th International Conference on Higher Education Advances (HEAd'21)

2021

Information and communication technologies together with new teaching paradigms are reshaping the learning environment.The International Conference on Higher Education Advances (HEAd) aims to become a forum for researchers and practitioners to exchange ideas, experiences,opinions and research results relating to the preparation of students and the organization of educational systems.

ECONOMIA APLICADAHigher educationCoronavirus disease 2019 (COVID-19)business.industryHead (linguistics)Online learningAdvancesLibrary scienceConferenceDesign thinkingHead'21EducationHigherCienciasInternationalComputingMilieux_COMPUTERSANDEDUCATIONECONOMIA FINANCIERA Y CONTABILIDADSociologybusiness
researchProduct

An ethical algorithm for rationing life sustaining treatment during the COVID-19 pandemic

2020

The burning ethical question raised by the COVID-19 pandemic is how to deal fairly and ethically with a large number of patients simultaneously becoming critically unwell. Across the world, in both developed and developing countries, health systems are grappling with the possibility or the reality that the demand for intensive medical care will outstrip availability. There is a need for ethical guidelines on how to allocate treatment, but such guidelines are potentially highly controversial.1 In this commentary, we set out a simple algorithm (Figure 1), including what we take to be the essential ethical principles that ought to guide resource allocation in any country or setting as well as …

Economic growth2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)utilitarianismPneumonia Viralresource allocationPersonal autonomyArticledecision makingSettore MED/02 - Storia Della MedicinaBetacoronavirusQuality of life (healthcare)Life sustaining treatmentSettore MED/43 - Medicina LegalePandemicHumansMedicinePandemicsSARS-CoV-2business.industryRationingCOVID-19ethicsTriageAnesthesiology and Pain MedicinePersonal AutonomyQuality of LifeethicprognosisCoronavirus InfectionsbusinesstriageAlgorithmsprognosi
researchProduct